Literature DB >> 23212279

A potential therapeutic system for Alzheimer's disease using adsorbents with alkyl ligands for removal of blood amyloid β.

Kazunori Kawaguchi1, Masato Takeuchi, Hiromasa Yamagawa, Kazutaka Murakami, Sigeru Nakai, Hideo Hori, Atsushi Ohashi, Yoshiyuki Hiki, Nobuo Suzuki, Satoshi Sugiyama, Yukio Yuzawa, Nobuya Kitaguchi.   

Abstract

Amyloid beta proteins (Aβ) in the brain are the main cause of Alzheimer's disease. Peripheral administration of Aβ-binding substances, which may act as a sink for Aβ from the brain, has been reported to reduce brain Aβ. We previously found C16-cellulose beads had high Aβ-removal activity in vitro. In this study, we investigated the optimum surface properties of adsorbents for removal of Aβ in vitro and in humans. Batch analysis was performed with porous cellulose beads or silica beads with or without 2-22 methylene groups. Aβ-removal activity of C16-cellulose beads increased with increasing alkyl chain length. In contrast, with cellulose the amount of Aβ removed by the silica beads decreased with increasing alkyl chain length. Cellulose beads with 16 or 22 methylene groups were best (over 99 % removal) among all the beads tested (p ≤ 0.01). The adsorbent surfaces were analyzed by near-infrared spectroscopy, which revealed that the optimum beads had a sufficiently hydrophobic surface with an appropriate amount of adsorbed water accessible on the surface. Aβ removal efficiency by C16-cellulose beads was investigated for 5 renal failure patients on hemodialysis, resulting in 51.1 ± 6.6 % for Aβ1-40 and 43.8 ± 4.5 % for Aβ1-42 (p ≤ 0.01). In conclusion, cellulose beads with 16 or 22 methylene groups and an appropriate amount of adsorbed water were the optimum Aβ adsorbents. The device with C16-cellulose beads had high Aβ removal activity in humans. These adsorbents might be useful for Alzheimer's disease therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23212279     DOI: 10.1007/s10047-012-0675-z

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  16 in total

Review 1.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

2.  Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid.

Authors:  Yasuji Matsuoka; Mitsuo Saito; John LaFrancois; Mariko Saito; Kate Gaynor; Vicki Olm; Lili Wang; Evelyn Casey; Yifan Lu; Chiharu Shiratori; Cynthia Lemere; Karen Duff
Journal:  J Neurosci       Date:  2003-01-01       Impact factor: 6.167

3.  Potential therapeutic system for Alzheimer's disease: removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patients.

Authors:  Masao Kato; Kazunori Kawaguchi; Sigeru Nakai; Kazutaka Murakami; Hideo Hori; Atsushi Ohashi; Yoshiyuki Hiki; Shinji Ito; Yasunobu Shimano; Nobuo Suzuki; Satoshi Sugiyama; Hiroshi Ogawa; Hiroko Kusimoto; Tatsuro Mutoh; Yukio Yuzawa; Nobuya Kitaguchi
Journal:  J Neural Transm (Vienna)       Date:  2012-06-15       Impact factor: 3.575

4.  Novel therapeutic approach for Alzheimer's disease by removing amyloid beta protein from the brain with an extracorporeal removal system.

Authors:  Kazunori Kawaguchi; Nobuya Kitaguchi; Shigeru Nakai; Kazutaka Murakami; Kunihiko Asakura; Tatsuro Mutoh; Yoshiro Fujita; Satoshi Sugiyama
Journal:  J Artif Organs       Date:  2010-02-23       Impact factor: 1.731

5.  Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

Authors:  Ronald B DeMattos; Kelly R Bales; David J Cummins; Steven M Paul; David M Holtzman
Journal:  Science       Date:  2002-03-22       Impact factor: 47.728

6.  Reduction of Alzheimer's disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions.

Authors:  N Kitaguchi; K Kawaguchi; S Nakai; K Murakami; S Ito; H Hoshino; H Hori; A Ohashi; Y Shimano; N Suzuki; Y Yuzawa; T Mutoh; S Sugiyama
Journal:  Blood Purif       Date:  2011-02-24       Impact factor: 2.614

7.  Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.

Authors:  Robert D Bell; Abhay P Sagare; Alan E Friedman; Gurrinder S Bedi; David M Holtzman; Rashid Deane; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2006-11-01       Impact factor: 6.200

8.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

Authors:  Christoph Hock; Uwe Konietzko; Johannes R Streffer; Jay Tracy; Andri Signorell; Britta Müller-Tillmanns; Ulrike Lemke; Katharina Henke; Eva Moritz; Esmeralda Garcia; M Axel Wollmer; Daniel Umbricht; Dominique J F de Quervain; Marc Hofmann; Alessia Maddalena; Andreas Papassotiropoulos; Roger M Nitsch
Journal:  Neuron       Date:  2003-05-22       Impact factor: 17.173

9.  Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease.

Authors:  Yinxing Liu; Christa Studzinski; Tina Beckett; Hanjun Guan; Matthew A Hersh; M Paul Murphy; Ronald Klein; Louis B Hersh
Journal:  Mol Ther       Date:  2009-05-26       Impact factor: 11.454

10.  Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity.

Authors:  Lin Wai Hung; Giuseppe D Ciccotosto; Eleni Giannakis; Deborah J Tew; Keyla Perez; Colin L Masters; Roberto Cappai; John D Wade; Kevin J Barnham
Journal:  J Neurosci       Date:  2008-11-12       Impact factor: 6.167

View more
  6 in total

Review 1.  Journal of Artificial Organs 2013: the year in review : Journal of Artificial Organs Editorial Committee.

Authors:  Y Sawa; E Tatsumi; T Tsukiya; K Matsuda; K Fukunaga; A Kishida; T Masuzawa; G Matsumiya; A Myoui; M Nishimura; T Nishimura; T Nishinaka; E Okamoto; S Tokunaga; T Tomo; Y Yagi; T Yamaoka
Journal:  J Artif Organs       Date:  2014-02-26       Impact factor: 1.731

2.  Toward the treatment for Alzheimer's disease: adsorption is primary mechanism of removing amyloid β protein with hollow-fiber dialyzers of the suitable materials, polysulfone and polymethyl methacrylate.

Authors:  Kazunori Kawaguchi; Akira Saigusa; Shinji Yamada; Takehiro Gotoh; Shigeru Nakai; Yoshiyuki Hiki; Midori Hasegawa; Yukio Yuzawa; Nobuya Kitaguchi
Journal:  J Artif Organs       Date:  2015-12-19       Impact factor: 1.731

3.  Aβ Influx into the Blood Evoked by Different Blood Aβ Removal Systems: A Potential Therapy for Alzheimer's Disease.

Authors:  Nobuya Kitaguchi; Kazunori Kawaguchi; Miwa Sakata; Hiroki Aoki; Kazunori Yamazaki; Megumi Kaneko; Jun Kinomura; Masao Kato; Midori Hasegawa; Nobuo Suzuki; Masao Mizuno; Yukio Yuzawa
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-13       Impact factor: 2.570

4.  Removal of blood amyloid-β with hemodialysis reduced brain amyloid-β, confirmed by brain imaging: a case report.

Authors:  Nobuya Kitaguchi; Takashi Kato; Shinji Matsunaga; Kyoko Hirano; Kaori Iwata; Kazunori Kawaguchi; Kiyoshi Fujita; Hajime Takechi; Midori Hasegawa; Yukio Yuzawa; Kengo Ito
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-01       Impact factor: 2.570

5.  Hydration of LiOH and LiCl-Near-Infrared Spectroscopic Analysis.

Authors:  Masato Takeuchi; Ryo Kurosawa; Junichi Ryu; Masaya Matsuoka
Journal:  ACS Omega       Date:  2021-11-24

6.  Removal of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer's Disease.

Authors:  Yuta Saito; Miwa Sakata; Moe Kobayakawa; Hiroshi Kawachi; Kazunori Kawaguchi; Yoshiyuki Hiki; Masao Kato; Mayuko Mori; Midori Hasegawa; Norimi Ohashi; Yukio Yuzawa; Nobuya Kitaguchi
Journal:  Neuropsychiatr Dis Treat       Date:  2020-03-03       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.